Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

atNorth Receives ISO14001 Certification

atNorth strengthens its commitment to improving its environmental management responsibilities.Stockholm, Sweden – April 24, 2023 –  atNorth , the leading Nordic colocation, high-performance computing, and artificial intelligence service provider, has announced that it has recently received an ISO14001 certification for Environmental Management for both its Iceland and Sweden sites. The accreditation demonstrates atNorth’s continued commitment to carbon reduction, not just through the development of state-of-the-art sustainable data centers, but also as a common

Bexmarilimab Efficacy and Safety in MATINS Trial

Faron Pharmaceuticals Oy   ("Faron or the Company")   Faron Announces Release of Research Confirming Bexmarilimab Efficacy and Safety in MATINS Trial   · Macrophage targeting can promote tumor stabilization in late-stage cancer · Bexmarilimab-induced macrophage activation with robust stimulation of IFN-γ and T-cell receptor signaling only in patients with disease control · Data confirms that bexmarilimab therapy is well-tolerated   Press Release, April 24, 2023   TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a

Clinical Laserthermia Systems intends to decide upon a rights issue of units of approximately SEK 135 million to support ongoing market introduction and strengthen the company's capital structure

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.   The board of directors of Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") announces its

Notice of AGM

24 April 2023 IOG plc  Notice of AGM IOG plc ("IOG", or "the Company"), (AIM: IOG.L) hereby gives notice of its 2023 Annual General Meeting (AGM). The Company's AGM will be held at 10.00am on 2 May 2023 at the offices of Fieldfisher, Riverbank House, 2 Swan Lane, London EC4R 3TT. The 2022 Annual Report and Accounts and the Notice of the Company's AGM was posted to shareholders on 6 April 2023. IOG is required to confirm all attendees ahead of the meeting. Shareholders wishing to join the AGM are therefore kindly requested to confirm their attendance by email to info@iog.co.uk

Handelsbanken’s Interim Report for January – March 2023 will be presented Wednesday 26 April

Handelsbanken publishes its interim report for January ­– March 2023, at 06:30 a.m. CET Wednesday, 26 April. The report, slide presentation and Fact Book will be published on handelsbanken.com/ir. The President and Group Chief Executive Officer Carina Åkerström will present the interim report at 08:30 a.m. CET. The presentation will be broadcast live in Swedish and available at handelsbanken.com/ir and with the option for simultaneous interpretation into English. The presentation will be followed by a short break, after which a Q&A session will be held in English for analysts,

Invitation to a press and analyst conference in Stockholm for presentation of Concentric’s Quarter One 2023 Interim Report

Concentric's Interim Report for Q1 January-March 2023, will be published on the 3 of May 2023, at 08.00 CET. At 10.00 CET media, investors and analysts are invited to Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm, for a presentation of the report. There will also be an opportunity to participate via webcast/telephone conference. President & CEO Martin Kunz and CFO Marcus Whitehouse will host the presentation, which will be held in English and is followed by a Q&A-session. We look forward to your participation. Please see the below detailed information to join in: Press

Nitro Games Oyj: Interim Report January – March 2023

Reporting period January – March 2023 · Revenues (Jan - Mar): 1 742,3 KEUR (1 133,3 KEUR). · EBITDA: -214,2 KEUR (-1 060,3 KEUR). · EBIT: - 462,1 KEUR (-1 262,8 KEUR). · Net result: -360,5 KEUR (-1 276,9 KEUR). · Earnings per share (EPS) 0,0 (-0,1). · Cash and cash equivalents: 1 683,4 KEUR, and 787,6 KEUR of short-term receivables (31 March 2023). (All figures are presented in accordance with IFRS and, unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year.) Significant events during January – March 2023

Kindred’s revenue from harmful gambling decreased to 3.0 per cent in the first quarter of 2023

In the first quarter of 2023, Kindred Group’s share of revenue from harmful gambling decreased to 3.0 per cent and the improvement effect after interventions was 83.0 per cent. During the quarter, effects of automated technological solutions such as detecting and engaging with customers at risk through automated interventions are showing initial signs of a positive trend.Kindred Group plc (Kindred) reports a decrease in the share of revenue from harmful gambling to 3.0 (3.3) per cent in the first quarter of 2023. This positive trend can be attributed to improvements focused on enhancing the

TOMRA: Invitation to Q1 2023 Presentation

TOMRA's first quarter 2023 results will be released Friday 28 April 2023. President & CEO Tove Andersen and CFO Eva Sagemo will present the results at 08:00 CEST. The presentation will be sent via live webcast. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the presentation. A recorded version of the webcast will be available shortly after the webcast has concluded. Link to the webcast:  https://channel.royalcast.com/landingpage/hegnarmedia/20230428_9/ All written materials including interim report,

Year-end report January-March 2023

A strong start to the year Quarter 1, 2023 · Incoming orders amounted to SEK 1,505m (1,345), equivalent to currency neutral growth of 5.9 percent compared with the same period last year. · Net sales amounted to SEK 1,482m (1,094), equivalent to currency neutral growth of 27.6 percent compared with the same period last year. · Adjusted EBITA was SEK 172.7m (115.7), giving an adjusted EBITAmargin of 11.7 percent (10.6). · Operating profit totalled SEK 127.1m (98.2), corresponding to an operating margin of 8.6 percent (9.0). Operating profit included a restructuring cost of

Metso Outotec has ended wind down and discontinued business in Russia

Metso Outotec Corporation’s press release on April 24, 2023 at 09:00 a.m. EESTMetso Outotec has not taken new orders from Russia since Russia’s attack on Ukraine in February 2022. To speed up discontinuation of contracts made before the war, the company started negotiating with its non-sanctioned customers to wind down open contracts.   This wind down process was completed in the first quarter of 2023, and Metso Outotec has since discontinued business with Russia.   To cover the costs of the wind down process, the company booked a non-recurring charge of EUR 150 million in the second

Continued steady growth for Bio-Works in first quarter – on the way to breakeven

Today, Bio-Works Technologies AB reported its sales development for the first quarter of 2023. Bio-Works revenues increased by +27% versus the prior year period. Total sales for the first quarter amounted to 7.6 MSEK. At the same time, order intake increased by 43% to 11.0 MSEK. The strongest growth was seen in order backlog which increased 210% during the period to 26.0 MSEK.Market conditions remain favorable despite a general slowdown in the biopharma-segment as result of economic uncertainties, inflation and increasing interest rates which have had a negative effect on access to capital—

2020 Bulkers Ltd. (2020) - Notice of Annual General Meeting 2023

Oslo, Norway, April 24, 2023 2020 Bulkers Ltd. (the “Company”) advises that the 2023 Annual General Meeting of the Company will be held on Tuesday, May 9th, 2023 at 4:00 p.m. CET at the Company’s office at Tjuvholmen Allé 3, 0252 Oslo, Norway.  The Board of Directors has fixed the close of business on Tuesday April 25, 2023 as the record date for determination of the shareholders entitled to attend and vote at the Annual General Meeting or any adjournment thereof. A copy of the Notice of Special General Meeting and Form of Proxy, and associated information including the Company’s

Arterial stiffness may cause metabolic syndrome in adolescents via an increase in fasting insulin and LDL cholesterol

Arterial stiffness may be a novel risk factor for metabolic syndrome in teens, a paper published in the American Journal of Physiology-Heart and Circulatory Physiology concludes. The study was conducted in collaboration between the University of Bristol in the UK, the University of Exeter in the UK, and the University of Eastern Finland.The World Health Organization describes metabolic syndrome as the constellation of three or more of the following: abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. The prevalence of metabolic syndrome in US middle-aged adults is 30%,

Katalysen Ventures AB (publ) appoints Anders Dahlgren as new CFO

Katalysen Ventures AB (publ) ("Katalysen" or the "Company") is pleased to announce the appointment of Anders Dahlgren as its new Chief Financial Officer (“CFO”). Anders will be taking over from the previous CFO, Joakim Helbig, and we wish Joakim all the best in his future endeavors.With Anders Dahlgren joining the team, Katalysen not only aims to further strengthen its own financial infrastructure, but also to provide more such support to the Company’s portfolio. Anders’ wealth of experience and expertise in financial management and entrepreneurship will help drive financial maturity in the

­Devyser enters agreement with Thermo Fisher Scientific for commercialization of Devyser’s post-transplant NGS products

· ­­Collaboration and distribution agreement with Thermo Fisher Scientific. · Thermo Fisher Scientific obtains exclusive rights to commercialize Devyser’s post-transplant monitoring portfolio in North America and Europe. Devyser Diagnostics AB (publ) today announced that the company has signed an exclusive collaboration and distribution agreement with Thermo Fisher Scientific. The agreement gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products in North America and Europe.“Partnering with Thermo Fisher, the

Asetek A/S – Start of subscription period for the Rights Issue

Aalborg, 24 April 2023. NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Reference is made to previous stock exchange announcements published on 8 March, 21 March, 31 March and 18 April 2023 from Asetek A/S (the "Company" or "Asetek") regarding a fully underwritten rights issue of 71,166,667 new shares in the Company (the "New Shares"), raising gross proceeds of NOK 213,500,001 equivalent to approximately DKK 140 million (the "

Aker ASA: Ex-dividend NOK 15.00 today

The shares in Aker ASA will be traded ex-dividend NOK 15.00 as from today, 24 April 2023. -ENDS- For more information, please contact: Investors:Fredrik Berge, Head of Investor Relations Aker ASATel: +47 450 32 090E-mail: fredrik.berge@akerasa.com Media: Atle Kigen, Head of Media Relations and Public Affairs Aker ASATel: +47 907 84 878E-mail: atle.kigen@akerasa.com This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Key information relating to cash dividend to be paid by Vår Energi ASA

Sandnes, Norway, 24 April 2023: The Board of Vår Energi ASA (OSE: VAR) has resolved to pay a dividend payment of NOK 1.148 per share, NOK 2 865 874 370 in total, equal to USD 270 million relating to Q1 2023. Dividend amount: 1.148 Announced currency: NOK Last day including right: 02.05.2023 Ex-date: 03.05.2023 Record date: 04.05.2023 Payment date: 10.05.2023 Date of approval: 21.04.2023 The dividend will be paid in NOK and the NOK dividend amount is based on the daily exchange rate published by Norges Bank 21 April 2023 approximately at 1600hrs CET. Contact

Vår Energi reports first quarter 2023 results

Vår Energi reports first quarter 2023 results Sandnes, Norway, 24 April 2023: Vår Energi ASA (OSE: VAR) reported USD 2 094 million in total income for the first quarter of 2023, a decrease of 12% from the fourth quarter 2022 primarily due to the timing of liftings. Profit before taxes was USD 1 276 million in the quarter, a decrease of around 29% compared to last quarter. Cash flow from operations (CFFO) was USD 1 358 million in the quarter, up from USD 445 million in the previous quarter. A dividend of USD 300 million (NOK 1.226 per share) for the fourth quarter of 2022 was paid in

Majlen Fazer rewarded the internationally esteemed ISM Award

Majlen Fazer has been selected as the recipient of the 2023 ISM Award. Majlen Fazer, the great-granddaughter of Fazer Group’s founder Karl Fazer, is a seasoned professional who has during her career worked with various tasks related to chocolate and its most important ingredient, cocoa. The award was handed to the winner on Sunday evening during an event organised in Cologne, Germany.The ISM Award is granted for a lifetime’s work and an exceptional contribution towards the development of the confectionery industry. The award, which this year was presented for the ninth time, is handed to an

Status - treasury shares buyback

Company announcement no. 22-23Copenhagen, April 23, 2023 Shape Robotics announced in company announcement no. 19-23 that it would seek to acquire approx. 75.000-100.000 treasury in the market (Nasdaq First North Copenhagen; Ticker: SHAPE) during the period April 17 and April 21 2023. Following transactions has been made in the period: April 17, 50.000 shares at DKK 24,00 pr. shareApril 21, 9.103 shares at DKK 23,80 pr. shareTotal 59.103 shares Additional information and investor relationsAndré Fehrn, CEOTlf.  (+45) 2444 8556Email: ir@shaperobotics.comRugmarken 18,

Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Oslo, 22 April 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and provider of high-quality products to hospitals and pharmacies, has today amended its cash offer to acquire all shares in Sensidose AB (the "Offer") and at the same time agreed to purchase 6,837,016 shares in Sensidose AB representing 57.2% of the outstanding shares. The Sensidose shares are currently listed on Spotlight Stock Market in Sweden.Navamedic ASA ("Navamedic") has today amended its Offer to SEK 8.00 per share in Sensidose AB ("Sensidose") representing a total purchase price of approximately SEK 96 million

There are no items matching the current filter
There are no more items matching the current filter
Back to top